Journal article
SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19
- Abstract:
-
Background
Monoclonal antibodies (mAbs) are laboratory‐produced molecules derived from the B cells of an infected host. They are being investigated as a potential therapy for coronavirus disease 2019 (COVID‐19).
Objectives
To assess the effectiveness and safety of SARS‐CoV‐2‐neutralising mAbs for treating patients with COVID‐19, compared to an active comparator, placebo, or no intervention. To maintain the currency of the evidence, we...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 2.5MB, Terms of use)
-
- Publisher copy:
- 10.1002/14651858.cd013825.pub2
Authors
- Publisher:
- Cochrane Collaboration
- Journal:
- Cochrane Database of Systematic Reviews More from this journal
- Volume:
- 2021
- Issue:
- 9
- Article number:
- CD013825
- Publication date:
- 2021-09-02
- Acceptance date:
- 2021-08-30
- DOI:
- EISSN:
-
1469-493X
- Language:
-
English
- Keywords:
- Pubs id:
-
1193917
- Local pid:
-
pubs:1193917
- Deposit date:
-
2021-09-06
Terms of use
- Copyright holder:
- Cochrane Collaboration
- Copyright date:
- 2021
- Rights statement:
- Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
If you are the owner of this record, you can report an update to it here: Report update to this record